1-(1,3-Oxazol-5-yl)propan-1-one | 2172473-41-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1,3-Oxazol-5-yl)propan-1-one
• CAS: 2172473-41-3
• 化学式: C₆H₇NO₂
• 分子量: 125.13
• InChiKey: IBDQWEAVPHTJES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
  申请人：Vazquez L. Michael

  公开号：US20070078173A1

  公开（公告）日：2007-04-05

  α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

  α-和β-氨基酸羟乙基氨磺酰胺化合物可作为逆转录病毒蛋白酶抑制剂，特别是作为HIV蛋白酶的抑制剂。
• [EN] ROCK INHIBITOR AND APPLICATION THEREOF<br/>[FR] INHIBITEUR DE ROCK SON APPLICATION<br/>[ZH] ROCK抑制剂及其应用
  申请人：HITGEN LTD

  公开号：WO2018108156A1

  公开（公告）日：2018-06-21

  式（I）所示的ROCK抑制剂及其制备方法和应用。试验表明，所述化合物具有良好的ROCK抑制活性，可以有效用于与ROCK活性异常疾病的治疗。
• LINKED DIBENZIMIDAZOLE DERIVATIVES
  申请人：Or Yat Sun

  公开号：US20100221214A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• LINKED DIIMIDAZOLE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20100226883A1

  公开（公告）日：2010-09-09

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110142798A1

  公开（公告）日：2011-06-16

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.